Giordano et al. demonstrated that p65BTK expression is controlled by the activation of the RAS/MAPK pathway by finding that both its expression and activity are downregulated in non-small cell lung cancer (NSCLC) cells treated with the MEK inhibitor trametinib [34]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.